Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Phase 3 trial records — page 14

351 records at phase 3.

Showing 0 records on this page

Records

351 documents · page 14 of 15

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
TA1-VACCINE-ELDERLY-REGIONAL-CNprogramme recordThymosin alpha-1Phase 3ReportedRandomised, double-blind, placebo-controlled1998Very low
IPA-PH1-GH-REGIONAL-CNprogramme recordIpamorelinPhase 3ReportedRandomised, double-blind, placebo-controlled1998Very low
HEX-PH2-ELDERLY-REGIONAL-CNprogramme recordHexarelinPhase 3ReportedRandomised, double-blind, placebo-controlled1997Very low
HEX-PH2-ELDERLY-REGIONAL-JPprogramme recordHexarelinPhase 3ReportedRandomised, double-blind, placebo-controlled1997Very low
TRIUMPH-1RetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
TRIUMPH-2RetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
TRIUMPH-3RetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
TRIUMPH-4RetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
TRIUMPH-OSARetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
REDEFINE-4CagriSema (cagrilintide with semaglutide)Phase 3OngoingRandomised, double-blind, active-controlledNot rated
SYNCHRONIZE-1SurvodutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
SYNCHRONIZE-2SurvodutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
SYNCHRONIZE-CVOTSurvodutidePhase 3OngoingEvent-driven cardiovascular outcome trialNot rated
DREAMS-3MazdutidePhase 3OngoingRandomised, double-blind, active-controlledNot rated
MARITIDE-PH3Maridebart cafraglutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
TRIUMPH-2-REGIONAL-CNprogramme recordRetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
TRIUMPH-3-OLEprogramme recordRetatrutidePhase 3OngoingSingle-arm open-labelVery low
TRIUMPH-4-BODY-COMPprogramme recordRetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
TRIUMPH-OSA-OLEprogramme recordRetatrutidePhase 3OngoingSingle-arm open-labelVery low
SYNCHRONIZE-1-ELDERLYprogramme recordSurvodutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
SYNCHRONIZE-2-REGIONAL-JPprogramme recordSurvodutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
DREAMS-3-BODY-COMPprogramme recordMazdutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
PETRE-PH2-OBESITY-REGIONAL-JPprogramme recordPetrelintidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
BPC-PH2-UC-REGIONAL-JPprogramme recordBPC-157Phase 3ReportedRandomised, double-blind, placebo-controlledVery low

page 14 of 15

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.